Core Viewpoint - TC BioPharm (Holdings) PLC has announced a special dividend of 0.25 American Depositary Shares (ADSs) for every 1 ADS held by shareholders, pending shareholder approval [1][2]. Group 1: Dividend Announcement - The special dividend is set to be declared on December 30, 2024, and will be payable to shareholders who own the Company's stock at the close of trading on January 2, 2025 [2]. - A general meeting of shareholders is scheduled for December 30, 2024, at The Seafield Arms Hotel in Scotland to discuss the dividend [1]. Group 2: Company Background - TC BioPharm is a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other indications, with human efficacy data in acute myeloid leukemia [6][7]. - The company is recognized as a leader in developing gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [7].
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend